As of April 28, 2026, Aurora Cannabis (ACB) is trading at , reflecting a 19.12% decline year-to-date . The company is currently executing a strategic shift to prioritize high-margin global medical cannabis markets over lower-margin consumer segments. Aurora Cannabis Inc (ACB) -19.12% since Jan 2, 2026 Closed: 4:00 PM • Disclaimer After hours: 7:30 PM Apr 27, 2026 Mkt cap$271.06M CAD 52-wk high6.67 P/E ratio- 52-wk low3.07 Div yield- Financial Performance & Health
: Reported $15.5 million in free cash flow for Q3 fiscal 2026, a critical milestone for long-term sustainability. buy acb stock
: While adjusted EBITDA reached $18.5 million , Aurora still reported a net loss of $51.6 million in Q3 2026, driven by costs rather than top-line movement alone. As of April 28, 2026, Aurora Cannabis (ACB)
: Global medical cannabis now accounts for 81% of total revenue and 95% of adjusted gross profit , with medical margins holding steady at 69% . Market Sentiment & Ratings : While adjusted EBITDA reached $18
Professional outlooks on ACB are mixed, balancing its medical leadership against broader sector risks.
Should You Buy, Hold or Sell ACB Stock Post Q3 Earnings Release?